These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 19702233)
1. Data protection for " innovative drugs"--guidance now final. McMahon E; Reguly T Health Law Can; 2009 May; 29(3):44-5. PubMed ID: 19702233 [No Abstract] [Full Text] [Related]
2. EU to review rare disease drugs market exclusivity. Sheridan C Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455 [No Abstract] [Full Text] [Related]
3. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
4. Supreme Court rules against drug patent "evergreening". Kondro W CMAJ; 2006 Dec; 175(12):1508-9. PubMed ID: 17146081 [No Abstract] [Full Text] [Related]
6. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development. Matthews JH Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357 [TBL] [Abstract][Full Text] [Related]
7. Canada decides to lead the way in exempting AIDS drugs from patent laws. Spurgeon D BMJ; 2003 Oct; 327(7419):832. PubMed ID: 14551093 [No Abstract] [Full Text] [Related]
8. Amendments to the Canadian Patent Act to address drug access: is help on the way? Penner MD; Narayanan P Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751 [No Abstract] [Full Text] [Related]
9. Drug patent law reform and shortages. Myronuk LD; Meagher JB CMAJ; 1993 Nov; 149(9):1225. PubMed ID: 8221466 [No Abstract] [Full Text] [Related]
11. Administrative drug submissions to be excluded from the PM(NOC) regulations? Cheung RY Health Law Can; 2011 Nov; 32(2):35. PubMed ID: 22259975 [No Abstract] [Full Text] [Related]
12. The patent-regulatory regime in Canada. Pei NP; Hamilton JS Pharm Pat Anal; 2012 Nov; 1(5):525-8. PubMed ID: 24236920 [No Abstract] [Full Text] [Related]
13. The drug bill: to the Americans it's only a start. Gray C CMAJ; 1988 Jan; 138(2):149-50. PubMed ID: 3334927 [No Abstract] [Full Text] [Related]
14. Patents: a threat to innovation? Manocaran M Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557 [No Abstract] [Full Text] [Related]
15. Sublicense or supply agreement? Supreme Court of Canada interpretation benefits generic pharmaceutical industry. Burshtein S Food Drug Law J; 1999; 54(1):73-91. PubMed ID: 11758562 [No Abstract] [Full Text] [Related]
16. Biotech patents-business as usual? Lawrence S Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861 [No Abstract] [Full Text] [Related]
17. Federal court invalidates Sanofi's Plavix patent for alleged insufficiency and obviousness. Folkins P Health Law Can; 2012 Feb; 32(3):46-8. PubMed ID: 22458154 [No Abstract] [Full Text] [Related]
19. [Patents in the pharmaceutical field: history and development of the institution]. Neri M Boll Chim Farm; 1995; 134(7):364-8. PubMed ID: 7546541 [TBL] [Abstract][Full Text] [Related]
20. Old drugs, new uses: solving a Hatch-Waxman patent predicament. McPhie DC Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929 [No Abstract] [Full Text] [Related] [Next] [New Search]